Incannex Healthcare Inc. Earnings Per Share Disclosure
Note 15 - Loss per share
All stock and earnings per share amounts presented below reflect the impact of the redomiciliation as if it had taken effect on July 1, 2022.
Basic and diluted net loss per share attributable to stockholders was calculated as follows:
| June 30, 2025 | June 30, 2024 | |||||||
| Basic and diluted loss per share (dollars per share) | 1.35 | 1.15 | ||||||
| The loss and weighted average number of shares of common stock used in the calculation of basic loss per share is as follows: | ||||||||
| Total comprehensive loss for the year (in thousands) | (46,677 | ) | (18,536 | ) | ||||
| - Weighted average number of shares of common stock (number) | 34,454,269 | 16,164,338 | ||||||
The Company notes that the diluted loss per share is the same as basic loss per share.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Sep 29, 2025 | Showing above |
| 2024 | Sep 30, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.